Althea Group (ASX:AGH)

  • Symbol:ASX:AGH
  • Sector:Healthcare
  • Industry:Pharmaceutical
  • CEO:Joshua Fegan
  • Founded:2017

Althea Group (ASX:AGH) Stock Price

Althea Group (ASX:AGH) Company Overview

The Althea Group's (ASX: AGH) mission is to corner the market on the importation, cultivation and supply of medical cannabis for patients Australia-wide.

After an IPO that saw the company raise $19.65 million in funding, it has since managed to push its' initial market capitalisation of $40.6 million all the way to $121.8 million. This puts it in the same league as some of the industry's biggest players, including AusCann and the Cann Group.

The Melbourne-based company has a three-stage business strategy focused on sales driven growth, scalable domestic production, and early revenue generation. It also intends to pursue strategic partnerships with companies such as the Canadian low-cost medical cannabis producer Aphria (TSE:APH), which owns a 25% stake in Althea.

Since Althea was founded in 2017 it has already managed to get five branded medicinal products on the market. Its' dedication to patient care also led to the development of the Althea Concierge, a web-based platform and mobile application intended to support access to medicinal cannabis.

Althea recently entered the UK and is already gaining traction in what will be a very large medicinal market.

Althea Group (ASX:AGH) Financials

More From Althea Group...

Althea Group Receives First Cannabis Prescription in UK
Pushing the Limits – Valens Scales Up Extraction Capacity and Receives TSXV Listing Approval
Althea Patients Increase 53% to hit 1,000 Patient Milestone
Exclusive Interview with Josh Fegan from Althea Group
Knock Out – CWEB Punches Through with CBD Gummies and Strong Q1 Results
Althea Given License to Grow Hemp in Victoria
Althea Group – Leading the Way in Patient Acquisition
Althea teams up with medicinal cannabis distributor to boost market presence
6 Australian cannabis stocks worth watching in 2019 – from creso pharma to mmj asx

Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Signup to get updates.


Joshua Fegan
Chief Executive Officer & Managing Director
Joshua Fegan is the founder of Althea Group. He has extensive experience in business building, sales and marketing, along with a range of proven business and strategy skills.

Fegan also founded Althea Health and Wellbeing in 2016—coinciding with registration of the ND Amendment Act, an Act to amend the ND Act, legalizing medicinal cannabis—and previously held a number of senior management roles at national value-based retailer, Strathfield Group.
Robert Meissner
Chief Financial Officer & Company Secretary
Robert Meissner was previously the Financial Controller for Village Cinemas, acting as a key advisor with responsibility for both the financial and commercial activities of the business.

Meissner started his career in private practice, before gaining experience in a number of roles and industries, including Advertising, Construction and Entertainment. He is also a Certified Practising Accountant.
Patty Holmes
Chief Operating Officer
Patty Holmes was previously the Director of Business Management at MDGH, where she oversaw the overall business management of the company including legal, financial, HR and statutory reporting requirements.

Prior to her role at MDGH, she worked with Gilead Sciences Australia, preparing patient and health-care professional facing materials for drugs launched in the Australian market. Holmes has also worked in New York as the Director of International Sales for SLM International Inc.